Gastric Cancer Therapy Global Market Report 2025

Description

Gastric cancer therapy encompasses the medical treatments aimed at managing and eradicating cancer that originates in the stomach lining. These treatments include surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy, which may be used alone or in combination based on the disease's stage and specific characteristics. The therapies function by killing rapidly dividing cancer cells, blocking molecular pathways that promote tumor growth, or activating the immune system to target cancer cells.

The primary categories of gastric cancer therapy are chemotherapy, targeted therapy, immunotherapy, radiation therapy, and surgery. Chemotherapy uses drugs to destroy rapidly dividing cancer cells throughout the body. These drugs are grouped into cytotoxic agents, monoclonal antibodies, tyrosine kinase inhibitors, checkpoint inhibitors, and other miscellaneous agents and can be delivered orally, intravenously, intramuscularly, or subcutaneously. These therapies are employed across various disease stages-including early, locally advanced, and metastatic and are used by multiple end users such as hospitals, oncology clinics, ambulatory surgical centers, research facilities, and home care providers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The gastric cancer therapy market research report is one of a series of new reports from The Business Research Company that provides gastric cancer therapy market statistics, including the gastric cancer therapy industry global market size, regional shares, competitors with the gastric cancer therapy market share, detailed gastric cancer therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the gastric cancer therapy industry. These gastric cancer therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gastric cancer therapy market size has grown strongly in recent years. It will grow from $4.12 billion in 2024 to $4.50 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth during the historical period can be attributed to the rising prevalence of H. pylori infection, increased tobacco and alcohol use, an expanding aging population, limited availability of early diagnostic methods, and the broad adoption of chemotherapy.

The gastric cancer therapy market size is expected to see strong growth in the next few years. It will grow to $6.39 billion in 2029 at a compound annual growth rate (CAGR) of 9.1%. The projected growth in the forecast period can be attributed to the rise of biomarker-based therapies, an increase in combination treatment strategies, growing investment in oncology research and development, expansion of healthcare infrastructure in emerging markets, and the adoption of liquid biopsies for monitoring. Key trends expected during this period include advancements in personalized medicine, emphasis on targeted drug delivery systems, a surge in clinical trials for new antibodies, integration of AI in diagnostic imaging, and the development of combination therapies.

The increasing prevalence of Helicobacter pylori infection is expected to drive the growth of the gastric cancer therapy market in the future. Helicobacter pylori is a bacterial infection that primarily affects the stomach lining and is a major cause of chronic gastritis and gastric cancer. The rise in Helicobacter pylori infections is mainly attributed to poor sanitation, as inadequate hygiene and contaminated food or water promote oral-oral or fecal-oral transmission of the bacteria. Gastric cancer therapy helps lower the risk of gastric cancer caused by Helicobacter pylori by treating the infection, reducing gastric inflammation and cellular damage, and preventing the progression from chronic gastritis and atrophic changes to malignant transformation of the stomach lining. For example, a report published by the Government of Canada in November 2024 stated that as of January 2023, the recurrence rate of H. pylori infection is estimated to be up to 19%, although this varies depending on geographic location and age. Thus, the growing prevalence of Helicobacter pylori infection is propelling the gastric cancer therapy market.

Leading companies in the gastric cancer therapy market are focusing on innovative treatments such as combination therapy to enhance treatment effectiveness and improve patient outcomes. Combination therapy uses two or more treatments-such as chemotherapy, targeted therapy, or immunotherapy-together to increase overall efficacy. In December 2024, BeOne Medicines Ltd., a China-based pharmaceutical company formerly known as BeiGene, received U.S. Food and Drug Administration (FDA) approval for Tevimbra (tislelizumab-jsgr) combined with platinum- and fluoropyrimidine-based chemotherapy as a first-line treatment for adults with unresectable or metastatic HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma whose tumors express PD-L1 (>=1). This approval was based on the Phase 3 RATIONALE-305 trial, which showed that the combination therapy improved median overall survival to 15.0 months compared to 12.9 months with chemotherapy alone, representing a 20% reduction in the risk of death. This achievement reflects a growing trend among pharmaceutical companies to invest in multimodal treatments that combine immunotherapy with traditional chemotherapy to improve clinical results, delay disease progression, and extend survival in advanced gastric cancer patients.

In January 2023, Leap Therapeutics Inc., a U.S.-based biotechnology firm, acquired Flame Biosciences Inc. for an undisclosed amount. This acquisition aims to bolster Leap Therapeutics' oncology pipeline by adding Flame Biosciences' clinical-stage anti-Claudin18.2 antibody FL-301 and two preclinical antibody programs, advancing the development of biomarker-targeted cancer therapies. Flame Biosciences Inc. is a U.S.-based biotechnology company specializing in gastric cancer therapies.

Major players in the gastric cancer therapy market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Astellas Pharma Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., BeiGene Ltd., Celltrion Healthcare Co. Ltd., Hutchison MediPharma Limited, Shanghai Henlius Biotech Inc., Imugene Limited, and LintonPharm Co. Ltd.

North America was the largest region in the gastric cancer therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gastric cancer therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gastric cancer therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gastric cancer therapy market consists of revenues earned by entities by providing services such as diagnostic testing and imaging, supportive care and palliative services, and clinical trial and research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastric cancer therapy market also includes sales of trastuzumab (Herceptin), nivolumab (Opdivo), ramucirumab (Cyramza), and fluorouracil-based chemotherapy, and endoscopic devices and imaging systems. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gastric Cancer Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gastric cancer therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gastric cancer therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gastric cancer therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Therapy Type: Chemotherapy; Targeted Therapy; Immunotherapy; Radiation Therapy; Surgery
2) By Drug Class: Cytotoxic Agents; Monoclonal Antibodies; Tyrosine Kinase Inhibitors; Checkpoint Inhibitors; Miscellaneous Agents
3) By Administration Route: Oral; Intravenous; Intramuscular; Subcutaneous
4) By Stage of Disease: Early Stage; Locally Advanced Stage; Metastatic Stage
5) By End User: Hospitals; Oncology Clinics; Ambulatory Surgical Centers; Research Institutions; Home Care Settings
Subsegments:
1) By Chemotherapy: Neoadjuvant Chemotherapy (NAC); Adjuvant Chemotherapy (AC); Palliative Chemotherapy (PC); Combination Chemotherapy; Monotherapy
2) By Targeted Therapy: Human Epidermal Growth Factor Receptor 2 (HER2) Targeted Therapy; Vascular Endothelial Growth Factor (VEGF) Inhibitors; Fibroblast Growth Factor Receptor (FGFR) Inhibitors; Mesenchymal-Epithelial Transition (MET) Inhibitors; Claudin 18 Isoform 2 Inhibitors
3) By Immunotherapy: Immune Checkpoint Inhibitors; Cancer Vaccines; Adoptive Cell Transfer; Cytokine Therapy; Combination Immunotherapy
4) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Intensity-Modulated Radiation Therapy (IMRT); Three-Dimensional Conformal Radiation Therapy (3D-CRT); Brachytherapy
5) By Surgery: Endoscopic Mucosal Resection (EMR); Endoscopic Submucosal Dissection (ESD); Subtotal Gastrectomy; Total Gastrectomy; Lymphadenectomy
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca PLC; Novartis AG; GSK plc; Eli Lilly and Company; Amgen Inc.; Teva Pharmaceutical Industries Ltd.; Otsuka Holdings Co. Ltd.; Astellas Pharma Inc.; Jiangsu Hengrui Pharmaceuticals Co. Ltd.; BeiGene Ltd.; Celltrion Healthcare Co. Ltd.; Hutchison MediPharma Limited; Shanghai Henlius Biotech Inc.; Imugene Limited; LintonPharm Co. Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r36996

1. Executive Summary

2. Gastric Cancer Therapy Market Characteristics

3. Gastric Cancer Therapy Market Trends And Strategies

4. Gastric Cancer Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Gastric Cancer Therapy Growth Analysis And Strategic Analysis Framework

5.1. Global Gastric Cancer Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Gastric Cancer Therapy Market Growth Rate Analysis
5.4. Global Gastric Cancer Therapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Gastric Cancer Therapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Gastric Cancer Therapy Total Addressable Market (TAM)

6. Gastric Cancer Therapy Market Segmentation

6.1. Global Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy
Targeted Therapy
Immunotherapy
Radiation Therapy
Surgery
6.2. Global Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cytotoxic Agents
Monoclonal Antibodies
Tyrosine Kinase Inhibitors
Checkpoint Inhibitors
Miscellaneous Agents
6.3. Global Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Intravenous
Intramuscular
Subcutaneous
6.4. Global Gastric Cancer Therapy Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Early Stage
Locally Advanced Stage
Metastatic Stage
6.5. Global Gastric Cancer Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Oncology Clinics
Ambulatory Surgical Centers
Research Institutions
Home Care Settings
6.6. Global Gastric Cancer Therapy Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Neoadjuvant Chemotherapy (NAC)
Adjuvant Chemotherapy (AC)
Palliative Chemotherapy (PC)
Combination Chemotherapy
Monotherapy
6.7. Global Gastric Cancer Therapy Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Human Epidermal Growth Factor Receptor 2 (HER2) Targeted Therapy
Vascular Endothelial Growth Factor (VEGF) Inhibitors
Fibroblast Growth Factor Receptor (FGFR) Inhibitors
Mesenchymal-Epithelial Transition (MET) Inhibitors
Claudin 18 Isoform 2 Inhibitors
6.8. Global Gastric Cancer Therapy Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immune Checkpoint Inhibitors
Cancer Vaccines
Adoptive Cell Transfer
Cytokine Therapy
Combination Immunotherapy
6.9. Global Gastric Cancer Therapy Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
External Beam Radiation Therapy (EBRT)
Intensity-Modulated Radiation Therapy (IMRT)
Three-Dimensional Conformal Radiation Therapy (3D-CRT)
Brachytherapy
6.10. Global Gastric Cancer Therapy Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Endoscopic Mucosal Resection (EMR)
Endoscopic Submucosal Dissection (ESD)
Subtotal Gastrectomy
Total Gastrectomy
Lymphadenectomy

7. Gastric Cancer Therapy Market Regional And Country Analysis

7.1. Global Gastric Cancer Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Gastric Cancer Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Gastric Cancer Therapy Market

8.1. Asia-Pacific Gastric Cancer Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Gastric Cancer Therapy Market

9.1. China Gastric Cancer Therapy Market Overview
9.2. China Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Gastric Cancer Therapy Market

10.1. India Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Gastric Cancer Therapy Market

11.1. Japan Gastric Cancer Therapy Market Overview
11.2. Japan Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Gastric Cancer Therapy Market

12.1. Australia Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Gastric Cancer Therapy Market

13.1. Indonesia Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Gastric Cancer Therapy Market

14.1. South Korea Gastric Cancer Therapy Market Overview
14.2. South Korea Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Gastric Cancer Therapy Market

15.1. Western Europe Gastric Cancer Therapy Market Overview
15.2. Western Europe Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Gastric Cancer Therapy Market

16.1. UK Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Gastric Cancer Therapy Market

17.1. Germany Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Gastric Cancer Therapy Market

18.1. France Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Gastric Cancer Therapy Market

19.1. Italy Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Gastric Cancer Therapy Market

20.1. Spain Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Gastric Cancer Therapy Market

21.1. Eastern Europe Gastric Cancer Therapy Market Overview
21.2. Eastern Europe Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Gastric Cancer Therapy Market

22.1. Russia Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Gastric Cancer Therapy Market

23.1. North America Gastric Cancer Therapy Market Overview
23.2. North America Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Gastric Cancer Therapy Market

24.1. USA Gastric Cancer Therapy Market Overview
24.2. USA Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Gastric Cancer Therapy Market

25.1. Canada Gastric Cancer Therapy Market Overview
25.2. Canada Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Gastric Cancer Therapy Market

26.1. South America Gastric Cancer Therapy Market Overview
26.2. South America Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Gastric Cancer Therapy Market

27.1. Brazil Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Gastric Cancer Therapy Market

28.1. Middle East Gastric Cancer Therapy Market Overview
28.2. Middle East Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Gastric Cancer Therapy Market

29.1. Africa Gastric Cancer Therapy Market Overview
29.2. Africa Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Gastric Cancer Therapy Market Competitive Landscape And Company Profiles

30.1. Gastric Cancer Therapy Market Competitive Landscape
30.2. Gastric Cancer Therapy Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Gastric Cancer Therapy Market Other Major And Innovative Companies

31.1. AstraZeneca PLC
31.2. Novartis AG
31.3. GSK plc
31.4. Eli Lilly and Company
31.5. Amgen Inc.
31.6. Teva Pharmaceutical Industries Ltd.
31.7. Otsuka Holdings Co. Ltd.
31.8. Astellas Pharma Inc.
31.9. Jiangsu Hengrui Pharmaceuticals Co. Ltd.
31.10. BeiGene Ltd.
31.11. Celltrion Healthcare Co. Ltd.
31.12. Hutchison MediPharma Limited
31.13. Shanghai Henlius Biotech Inc.
31.14. Imugene Limited
31.15. LintonPharm Co. Ltd.

32. Global Gastric Cancer Therapy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gastric Cancer Therapy Market

34. Recent Developments In The Gastric Cancer Therapy Market

35. Gastric Cancer Therapy Market High Potential Countries, Segments and Strategies

35.1 Gastric Cancer Therapy Market In 2029 - Countries Offering Most New Opportunities
35.2 Gastric Cancer Therapy Market In 2029 - Segments Offering Most New Opportunities
35.3 Gastric Cancer Therapy Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer